Cancer Therapy

You have full text access to this OnlineOpen article

Aldo–keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention

  1. Ruilan Yan1,
  2. Xuyu Zu1,2,
  3. Jun Ma1,
  4. Ziwen Liu1,
  5. Moses Adeyanju3,
  6. Deliang Cao1,†,*

Article first published online: 27 JUN 2007

DOI: 10.1002/ijc.22933

Issue

International Journal of Cancer

International Journal of Cancer

Volume 121, Issue 10, pages 2301–2306, 15 November 2007

Additional Information

How to Cite

Yan, R., Zu, X., Ma, J., Liu, Z., Adeyanju, M. and Cao, D. (2007), Aldo–keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention. Int. J. Cancer, 121: 2301–2306. doi: 10.1002/ijc.22933

Author Information

  1. 1

    Department of Medical Microbiology, Immunology and Cell Biology, SimmonsCooper Cancer Institute, Southern Illinois University School of Medicine, Springfield, IL

  2. 2

    Division of Pharmacoproteomics, Institute of Pharmacy and Pharmacology, Nanhua University School of Life Science and Technology, Hengyang, Hunan, China

  3. 3

    Department of Pathology, Memorial Hospital of Carbondale, Carbondale, IL

  1. †

    Fax: +217-545-9718.

*Department of Medical Microbiology, Immunology and Cell Biology, SimmonsCooper Cancer Institute, Southern Illinois University School of Medicine, 913 N. Rutledge Street, Springfield, IL 62702, USA

Publication History

  1. Issue published online: 25 SEP 2007
  2. Article first published online: 27 JUN 2007
  3. Manuscript Accepted: 9 MAY 2007
  4. Manuscript Received: 28 FEB 2007

Funded by

  • American Cancer Society. Grant Number: RSG-04-031-01-CCE

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (348K)

References

  • 1
    Cao D, Fan ST, Chung SS. Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 1998; 273: 11429–35.
  • 2
    Lefrancois-Martinez AM, Bertherat J, Val P, Tournaire C, Gallo-Payet N, Hyndman D, Veyssiere G, Bertagna X, Jean C, Martinez A. Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors. J Clin Endocrinol Metab 2004; 89: 3010–9.
  • 3
    Hyndman D, Bauman DR, Heredia VV, Penning TM. The aldo-keto reductase superfamily homepage. Chem Biol Interact 2003; 143/144: 621–31.
  • 4
    Jin J, Krishack PA, Cao D. Role of aldo-keto reductases in development of prostate and breast cancer. Front Biosci 2006; 11: 2767–73.
  • 5
    Saraswat M, Mrudula T, Kumar PU, Suneetha A, Rao Rao TS, Srinivasulu M, Reddy B. Overexpression of aldose reductase in human cancer tissues. Med Sci Monit 2006; 12: CR525–CR9.
  • 6
    Takahashi M, Fujii J, Miyoshi E, Hoshi A, Taniguchi N. Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes. Int J Cancer 1995; 62: 749–54.
    Direct Link:
  • 7
    Lee EK, Regenold WT, Shapiro P. Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases. Anticancer Drugs 2002; 13: 859–68.
  • 8
    Lee KW, Ko BC, Jiang Z, Cao D, Chung SS. Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs 2001; 12: 129–32.
  • 9
    Tammali R, Ramana KV, Singhal SS, Awasthi S, Srivastava SK. Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin e2 production in human colon cancer cells. Cancer Res 2006; 66: 9705–13.
  • 10
    Ramana KV, Chandra D, Srivastava S, Bhatnagar A, Aggarwal BB, Srivastava SK. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J Biol Chem 2002; 277: 32063–70.
  • 11
    Ramana KV, Bhatnagar A, Srivastava SK. Aldose reductase regulates TNF-alpha-induced cell signaling and apoptosis in vascular endothelial cells. FEBS Lett 2004; 570: 189–94.
  • 12
    Fukumoto S, Yamauchi N, Moriguchi H, Hippo Y, Watanabe A, Shibahara J, Taniguchi H, Ishikawa S, Ito H, Yamamoto S, Iwanari H, Hironaka M, et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 2005; 11: 1776–85.
  • 13
    Penning TM. AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers. Clin Cancer Res 2005; 11: 1687–90.
  • 14
    Zu X, Yan R, Robbins S, Krishack PA, Liao DF, Cao D. Reduced 293T cell susceptibility to acrolein due to aldose reductase-like-1 protein expression. Toxicol Sci 2007; 97: 562–8.
  • 15
    Ames BN. Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science 1983; 221: 1256–64.
  • 16
    Miyata T, Kurokawa K, Van Ypersele De Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000; 11: 1744–52.
  • 17
    De Bont R, van Larebeke N. Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis 2004; 19: 169–85.
  • 18
    Kurtz AJ, Lloyd RS. 1,N2-deoxyguanosine adducts of acrolein, crotonaldehyde, and trans-4-hydroxynonenal cross-link to peptides via Schiff base linkage. J Biol Chem 2003; 278: 5970–6.
  • 19
    Hashimoto M, Sibata T, Wasada H, Toyokuni S, Uchida K. Structural basis of protein-bound endogenous aldehydes. Chemical and immunochemical characterizations of configurational isomers of a 4-hydroxy-2-nonenal-histidine adduct. J Biol Chem 2003; 278: 5044–51.
  • 20
    Eder EB. Cancer risk assessment for the environmental mutagen and carcinogen crotonaldehyde on the basis of TD(50) and comparison with 1,N(2)-propanodeoxyguanosine adduct levels. Cancer Epidemiol Biomarkers Prev 2001; 10: 883–8.
  • 21
    Yang IY, Chan G, Miller H, Huang Y, Torres MC, Johnson F, Moriya M. Mutagenesis by acrolein-derived propanodeoxyguanosine adducts in human cells. Biochemistry 2002; 41: 13826–32.
  • 22
    Nagy E, Zeisig M, Kawamura K, Hisamatsu Y, Sugeta A, Adachi S, Moller L. DNA adduct and tumor formations in rats after intratracheal administration of the urban air pollutant 3-nitrobenzanthrone. Carcinogenesis 2005; 26: 1821–8.
  • 23
    Cline SD, Riggins JN, Tornaletti S, Marnett LJ, Hanawalt PC. Malondialdehyde adducts in DNA arrest transcription by T7 RNA polymerase and mammalian RNA polymerase II. Proc Natl Acad Sci USA 2004; 101: 7275–80.
  • 24
    Wilkins RC, Kutzner BC, Truong M, Sanchez-Dardon J, McLean JR. Analysis of radiation-induced apoptosis in human lymphocytes: flow cytometry using Annexin V and propidium iodide versus the neutral comet assay. Cytometry 2002; 48: 14–19.
    Direct Link:
  • 25
    Munshi A, Hobbs M, Meyn RE. Clonogenic cell survival assay. Methods Mol Med 2005; 110: 21–8.
  • 26
    Pessina A, Malerba I, Gribaldo L. Hematotoxicity testing by cell clonogenic assay in drug development and preclinical trials. Curr Pharm Des 2005; 11: 1055–65.
  • 27
    Feron VJ, Til HP, de Vrijer F, Woutersen RA, Cassee FR, van Bladeren PJ. Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment. Mutat Res 1991; 259: 363–85.
  • 28
    Fontaine FR, Dunlop RA, Petersen DR, Burcham PC. Oxidative bioactivation of crotyl alcohol to the toxic endogenous aldehyde crotonaldehyde: association of protein carbonylation with toxicity in mouse hepatocytes. Chem Res Toxicol 2002; 15: 1051–8.
  • 29
    Balu N, Gamcsik MP, Colvin ME, Colvin OM, Dolan ME, Ludeman SM. Modified guanines representing O(6)-alkylation by the cyclophosphamide metabolites acrolein and chloroacetaldehyde: synthesis, stability, and ab initio studies. Chem Res Toxicol 2002; 15: 380–7.
  • 30
    Sladek NE. Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 2003; 17: 7–23.
    Direct Link:
  • 31
    Nyska A, Moomaw CR, Lomnitski L, Chan PC. Glutathione S-transferase pi expression in forestomach carcinogenesis process induced by gavage-administered 2,4-hexadienal in the F344 rat. Arch Toxicol 2001; 75: 618–24.
  • 32
    Coles BF, Kadlubar FF. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? Biofactors 2003; 17: 115–30.
    Direct Link:
  • 33
    Vander Jagt DL, Kolb NS, Vander Jagt TJ, Chino J, Martinez FJ, Hunsaker LA, Royer RE. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim Biophys Acta 1995; 1249: 117–26.
  • 34
    Homann N, Tillonen J, Salaspuro M. Microbially produced acetaldehyde from ethanol may increase the risk of colon cancer via folate deficiency. Int J Cancer 2000; 86: 169–73.
    Direct Link:
  • 35
    Van Cruchten S, Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002; 31: 214–23.
    Direct Link:
View Full Article (HTML) Get PDF (348K)